UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (date of earliest event reported): January 16, 2006


                               CEL-SCI CORPORATION
                               -------------------
             (Exact name of Registrant as specified in its charter)


     Colorado                          1-11889                  84-0916344
--------------------              ------------------       ------------------
(State or other jurisdiction     (Commission File No.)        (IRS Employer
of incorporation)                                           Identification No.)

                              8229 Boone Blvd. #802
                                Vienna, VA 22182
--------------------------------------------------------------------------------
          (Address of principal executive offices, including Zip Code)


       Registrant's telephone number, including area code: (703) 506-9460
                                                           --------------

                                       N/A
                 ----------------------------------------- ----
          (Former name or former address if changed since last report)


Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-14(c) under the
    Exchange Act (17 CFR 240.13e-4(c))


<PAGE>


Item 3.01   Notice of Request to American Stock Exchange for Extension time
            to File the Company's 10-K with the SEC and to Distribute the Annual
            Report to Shareholders

      CEL-SCI's common stock is traded on the American Stock Exchange (AMEX).
The rules of the American Stock Exchange require CEL-SCI to file its 10-K with
the SEC in a timely manner and to furnish its shareholders with an annual report
no later than four months after the end of CEL-SCI's fiscal year. The AMEX rules
also permit an extension of the time to distribute an annual report if there is
good cause for delay. CEL-SCI, on January 17, 2006, requested an extension from
the AMEX until February 28, 2006 to file its 10-K with the SEC and another
extension to distribute its annual report to its shareholders no later than
April 15, 2006. In that letter CEL-SCI explained that it had never previously
been late for any of its financial filings, that it has, diligently, been trying
to resolve certain issues described below and that it has hired a third
accounting firm to resolve these complicated issues in a timely manner.

      Subsequent to the issuance of CEL-SCI's June 30, 2005 Form 10-Q, CEL-SCI
determined that there may be restatements in its previously issued financial
statements. All of the restatements discussed herein are of a non-cash nature
and do not affect the CEL-SCI's cash position. CEL-SCI is working to complete
its evaluation of the transactions in question, which involve certain financial
instruments issued by CEL-SCI between August 18, 2001 and November 28, 2003,
specifically, Series E Preferred Stock, the Cambrex Convertible Debt, Series F,
G and H Convertible Securities, the equity line agreements, as well as Series I
and J common stock financings, and any warrants associated with these
transactions. Although CEL-SCI has not completed its evaluation, it has
tentatively concluded that these instruments contain derivatives or embedded
derivatives which will need to be accounted for under Statement of Financial
Accounting Standards No. 133, Accounting for Derivative Instruments and Hedging
Activities, ("FAS 133") and under Emerging Issues Task Force Issue No. 00-19,
Accounting for Derivative Financial Instruments Indexed to, and Potentially
Settled in, a Company's Own Stock, ("EITF 00-19"). Simplistically, these
instruments should be accounted for as assets or liabilities and
marked-to-market at the end of each reporting period until certain conditions
have been met, the instruments expire, or the instruments are converted to
equity. When such instruments no longer require mark-to-market accounting, such
instruments will be reclassified from assets or liabilities to equity. Until
such analyses are completed, the Company is unable to determine exactly the
impact on previously filed interim and audited financial statements.

Item 4.02(a)  Non-Reliance on Previously Issued Financial  Statements or a
              Related Audit Report or Completed Interim Review.

      On January 16, 2006, CEL-SCI's audit committee concluded that CEL-SCI's
financial statements for the annual and interim periods in fiscal years 2001,
2002, 2003, and 2004, the fiscal year 2005 quarterly reporting periods of
December 31, 2004, March 31, 2005 and June 30, 2005, and the related audit
reports of our former independent registered public accounting firm, Deloitte &
Touche LLP, should no longer be relied upon as a result of identified errors in
the accounting for certain transactions, which are expected to require
restatement of the Company's historical financial statements. Until such
analyses are completed, the Company is unable to determine exactly the impact on
previously filed interim and audited financial statements.


                                       2

<PAGE>


      CEL-SCI is working to complete its evaluation of the transactions in
question, which involve certain financial instruments issued by CEL-SCI between
August 18, 2001 and November 28, 2003, specifically, Series E Preferred Stock,
the Cambrex Convertible Debt, Series F, G and H Convertible Securities, the
equity line agreements, as well as Series I and J common stock financings, and
any warrants associated with these transactions. Although CEL-SCI has not
completed its evaluation, it has tentatively concluded that these instruments
contain derivatives or embedded derivatives which will need to be accounted for
under Statement of Financial Accounting Standards No. 133, Accounting for
Derivative Instruments and Hedging Activities, ("FAS 133") and under Emerging
Issues Task Force Issue No. 00-19, Accounting for Derivative Financial
Instruments Indexed to, and Potentially Settled in, a Company's Own Stock,
("EITF 00-19"). Simplistically, these instruments should be accounted for as
assets or liabilities and marked-to-market at the end of each reporting period
until certain conditions have been met, the instruments expire, or the
instruments are converted to equity. When such instruments no longer require
mark-to-market accounting, such instruments will be reclassified from assets or
liabilities to equity.

      Geert Kersten, CEL-SCI's Chief Executive Officer discussed the matters
disclosed in this 8-K report with the audit committee of CEL-SCI, Deloitte &
Touche LLP, CEL-SCI's former independent registered public accounting firm, and
BDO Seidman, CEL-SCI's independent registered public accounting firm.

Item 9.01   Financial Statements, Exhibits and Pro Forma Financial Information

      (d)   Exhibits

           None


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date:  January 18, 2006.

                                 CEL-SCI CORPORATION



                                 By:   /s/ Geert R. Kersten
                                      ----------------------------------------
                                      Geert R. Kersten, Chief Executive Officer




                                       3
[{"type": "8-K", "sequence": "1", "filename": "form8k1-06.txt", "secsgml_size_bytes": 8270}]
{"company-data": {"conformed-name": "CEL SCI CORP", "cik": "0000725363", "assigned-sic": "2836", "irs-number": "840916344", "state-of-incorporation": "CO", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-11889", "film-number": "06536214"}, "business-address": {"street1": "8229 BOONE BLVD .", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182", "phone": "7035069460"}, "mail-address": {"street1": "8229 BOONE BLVD.", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182"}, "former-company": {"former-conformed-name": "INTERLEUKIN 2 INC", "date-changed": "19880317"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (date of earliest event reported): January 16, 2006

                               CEL-SCI CORPORATION
                               -------------------
             (Exact name of Registrant as specified in its charter)

     Colorado                          1-11889                  84-0916344
--------------------              ------------------       ------------------
(State or other jurisdiction     (Commission File No.)        (IRS Employer
of incorporation)                                           Identification No.)

                              8229 Boone Blvd. #802
                                Vienna, VA 22182
--------------------------------------------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (703) 506-9460
                                                           --------------

                                       N/A
                 ----------------------------------------- ----
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-14(c) under the
    Exchange Act (17 CFR 240.13e-4(c))
Item 3.01   Notice of Request to American Stock Exchange for Extension time
            to File the Company's 10-K with the SEC and to Distribute the Annual
            Report to Shareholders

      CEL-SCI's common stock is traded on the American Stock Exchange (AMEX).
The rules of the American Stock Exchange require CEL-SCI to file its 10-K with
the SEC in a timely manner and to furnish its shareholders with an annual report
no later than four months after the end of CEL-SCI's fiscal year. The AMEX rules
also permit an extension of the time to distribute an annual report if there is
good cause for delay. CEL-SCI, on January 17, 2006, requested an extension from
the AMEX until February 28, 2006 to file its 10-K with the SEC and another
extension to distribute its annual report to its shareholders no later than
April 15, 2006. In that letter CEL-SCI explained that it had never previously
been late for any of its financial filings, that it has, diligently, been trying
to resolve certain issues described below and that it has hired a third
accounting firm to resolve these complicated issues in a timely manner.

      Subsequent to the issuance of CEL-SCI's June 30, 2005 Form 10-Q, CEL-SCI
determined that there may be restatements in its previously issued financial
statements. All of the restatements discussed herein are of a non-cash nature
and do not affect the CEL-SCI's cash position. CEL-SCI is working to complete
its evaluation of the transactions in question, which involve certain financial
instruments issued by CEL-SCI between August 18, 2001 and November 28, 2003,
specifically, Series E Preferred Stock, the Cambrex Convertible Debt, Series F,
G and H Convertible Securities, the equity line agreements, as well as Series I
and J common stock financings, and any warrants associated with these
transactions. Although CEL-SCI has not completed its evaluation, it has
tentatively concluded that these instruments contain derivatives or embedded
derivatives which will need to be accounted for under Statement of Financial
Accounting Standards No. 133, Accounting for Derivative Instruments and Hedging
Activities, ("FAS 133") and under Emerging Issues Task Force Issue No. 00-19,
Accounting for Derivative Financial Instruments Indexed to, and Potentially
Settled in, a Company's Own Stock, ("EITF 00-19"). Simplistically, these
instruments should be accounted for as assets or liabilities and
marked-to-market at the end of each reporting period until certain conditions
have been met, the instruments expire, or the instruments are converted to
equity. When such instruments no longer require mark-to-market accounting, such
instruments will be reclassified from assets or liabilities to equity. Until
such analyses are completed, the Company is unable to determine exactly the
impact on previously filed interim and audited financial statements.

Item 4.02(a)  Non-Reliance on Previously Issued Financial  Statements or a
              Related Audit Report or Completed Interim Review.

      On January 16, 2006, CEL-SCI's audit committee concluded that CEL-SCI's
financial statements for the annual and interim periods in fiscal years 2001,
2002, 2003, and 2004, the fiscal year 2005 quarterly reporting periods of
December 31, 2004, March 31, 2005 and June 30, 2005, and the related audit
reports of our former independent registered public accounting firm, Deloitte &
Touche LLP, should no longer be relied upon as a result of identified errors in
the accounting for certain transactions, which are expected to require
restatement of the Company's historical financial statements. Until such
analyses are completed, the Company is unable to determine exactly the impact on
previously filed interim and audited financial statements.

                                       2
CEL-SCI is working to complete its evaluation of the transactions in
question, which involve certain financial instruments issued by CEL-SCI between
August 18, 2001 and November 28, 2003, specifically, Series E Preferred Stock,
the Cambrex Convertible Debt, Series F, G and H Convertible Securities, the
equity line agreements, as well as Series I and J common stock financings, and
any warrants associated with these transactions. Although CEL-SCI has not
completed its evaluation, it has tentatively concluded that these instruments
contain derivatives or embedded derivatives which will need to be accounted for
under Statement of Financial Accounting Standards No. 133, Accounting for
Derivative Instruments and Hedging Activities, ("FAS 133") and under Emerging
Issues Task Force Issue No. 00-19, Accounting for Derivative Financial
Instruments Indexed to, and Potentially Settled in, a Company's Own Stock,
("EITF 00-19"). Simplistically, these instruments should be accounted for as
assets or liabilities and marked-to-market at the end of each reporting period
until certain conditions have been met, the instruments expire, or the
instruments are converted to equity. When such instruments no longer require
mark-to-market accounting, such instruments will be reclassified from assets or
liabilities to equity.

      Geert Kersten, CEL-SCI's Chief Executive Officer discussed the matters
disclosed in this 8-K report with the audit committee of CEL-SCI, Deloitte &
Touche LLP, CEL-SCI's former independent registered public accounting firm, and
BDO Seidman, CEL-SCI's independent registered public accounting firm.

Item 9.01   Financial Statements, Exhibits and Pro Forma Financial Information

      (d)   Exhibits

           None

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  January 18, 2006.

                                 CEL-SCI CORPORATION

                                 By:   /s/ Geert R. Kersten
                                      ----------------------------------------
                                      Geert R. Kersten, Chief Executive Officer

                                       3